677 related articles for article (PubMed ID: 820877)
1. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Morales A; Eidinger D; Bruce AW
J Urol; 1976 Aug; 116(2):180-3. PubMed ID: 820877
[TBL] [Abstract][Full Text] [Related]
2. Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors.
Morales A; Eidinger D; Bruce AW
J Urol; 2017 Feb; 197(2S):S142-S145. PubMed ID: 28012770
[TBL] [Abstract][Full Text] [Related]
3. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
5. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
6. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Brosman SA
J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
8. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
9. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.
Zlotta AR; Drowart A; Van Vooren JP; Shekarsarai H; De Cock M; Pirson M; Palfliet K; Jurion F; Simon J; Schulman CC; Huygen K
J Urol; 1998 Jun; 159(6):1885-91. PubMed ID: 9598481
[TBL] [Abstract][Full Text] [Related]
10. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
11. Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.
Ardelt PU; Kneitz B; Adam P; Reiss C; Kocot A; Fensterle J; Chen L; Pasqualini R; Arap W; Gerharz EW; Riedmiller H
Cancer; 2010 Feb; 116(3):600-9. PubMed ID: 19957324
[TBL] [Abstract][Full Text] [Related]
12. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
14. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
Bunimovich-Mendrazitsky S; Byrne H; Stone L
Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
[TBL] [Abstract][Full Text] [Related]
15. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
16. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
17. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy of superficial bladder cancer].
Schmitz-Dräger BJ; Schattka SO; Ebert T
Urologe A; 1993 Sep; 32(5):374-81. PubMed ID: 8212422
[TBL] [Abstract][Full Text] [Related]
19. Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy.
Nissenkorn I; Lavie G; Keisari Y; Leib Z; Vilcovsky E; Servadio C; Shachter H
Eur Urol; 1987; 13(4):246-50. PubMed ID: 2820737
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.
Patard JJ; Chopin DK; Boccon-Gibod L
World J Urol; 1993; 11(3):165-8. PubMed ID: 8401636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
